PMID- 29419934
OWN - NLM
STAT- MEDLINE
DCOM- 20180821
LR  - 20211204
IS  - 1476-4431 (Electronic)
IS  - 1476-4431 (Linking)
VI  - 28
IP  - 2
DP  - 2018 Mar
TI  - Evaluation of nafamostat mesilate as an alternative anticoagulant during 
      intermittent hemodialysis in healthy Beagle dogs.
PG  - 122-129
LID - 10.1111/vec.12696 [doi]
AB  - OBJECTIVE: To evaluate nafamostat mesilate (NM) as an alternative anticoagulant 
      agent for intermittent hemodialysis (IHD). DESIGN: Prospective randomized study. 
      SETTING: University teaching hospital. ANIMALS: Eighteen healthy Beagle dogs. 
      INTERVENTIONS: In group 1 (n = 6), NM was administered at a dose of 0.5 mg/kg/h 
      during IHD for 5 hours. In group 2 (n = 6), NM was administered at a low dose of 
      0.25 mg/kg/h during IHD. In group 3 (n = 6), which was the control group, 
      unfractionated heparin (UFH) was administered during IHD. The evaluated 
      parameters included: the amount of residual blood clots in the blood chamber and 
      arterial side of the dialyzer; the levels of hemoglobin, hematocrit, and 
      platelets; and the prothrombin time (PT), activated partial thromboplastin time 
      (aPTT), and activated clotting time (ACT). MEASUREMENTS AND MAIN RESULTS: Groups 
      1 and 2 successfully completed IHD without serious coagulation in the 
      extracorporeal circulation. The residual blood clotting in the blood chamber and 
      arterial side of the dialyzer did not significantly differ in groups 1 and 2 
      compared to group 3 (group 1 vs group 3, P = 1.000; and group 2 vs group 3, P = 
      1.000). No significant differences were observed between pre- and posttreatment 
      PTs in groups 1 (P = 0.476) and 2 (P = 0.597), between pre- and posttreatment 
      aPTTs in groups 1 (P = 0.983) and 2 (P = 0.977), and between pre- and 
      posttreatment ACT in groups 1 (P = 0.282) and 2 (P = 0.401). In group 3, a 
      significant elevation of ACT was observed at the posttest (P < 0.001). 
      CONCLUSIONS: The results of this study in healthy Beagle dogs suggest that NM at 
      0.25 mg/kg/h may be a valid alternative to UFH for IHD. Further studies are 
      needed in patients at high risk of bleeding.
CI  - (c) Veterinary Emergency and Critical Care Society 2018.
FAU - Choi, Joon-Hyuk
AU  - Choi JH
AD  - Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine,, 
      Chungnam National University, Daejeon 305-764, South Korea.
FAU - Byun, Seok-Yeong
AU  - Byun SY
AD  - Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine,, 
      Chungnam National University, Daejeon 305-764, South Korea.
FAU - Nam, Aryung
AU  - Nam A
AD  - the Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, 
      Seoul National University, Seoul, South Korea.
FAU - Han, Sei-Myoung
AU  - Han SM
AD  - the Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, 
      Seoul National University, Seoul, South Korea.
FAU - Lee, Kyu-Pil
AU  - Lee KP
AD  - the Laboratory of Veterinary Physiology College of Veterinary Medicine, Chungnam 
      National University, Daejeon 305-764, South Korea.
FAU - Song, Kun-Ho
AU  - Song KH
AD  - Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine,, 
      Chungnam National University, Daejeon 305-764, South Korea.
FAU - Youn, Hwa-Young
AU  - Youn HY
AD  - the Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, 
      Seoul National University, Seoul, South Korea.
FAU - Seo, Kyoung-Won
AU  - Seo KW
AUID- ORCID: 0000-0002-1561-3278
AD  - Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine,, 
      Chungnam National University, Daejeon 305-764, South Korea.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180208
PL  - United States
TA  - J Vet Emerg Crit Care (San Antonio)
JT  - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
JID - 101152804
RN  - 0 (Anticoagulants)
RN  - 0 (Benzamidines)
RN  - 0 (Guanidines)
RN  - 9005-49-6 (Heparin)
RN  - Y25LQ0H97D (nafamostat)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*therapeutic use
MH  - Benzamidines
MH  - Blood Coagulation/drug effects
MH  - Dogs
MH  - Female
MH  - Guanidines/*therapeutic use
MH  - Heparin/pharmacology
MH  - Humans
MH  - Male
MH  - Partial Thromboplastin Time/veterinary
MH  - Prospective Studies
MH  - Prothrombin Time/veterinary
MH  - Renal Dialysis/*veterinary
OTO - NOTNLM
OT  - anticoagulation
OT  - canine
OT  - dialysis
OT  - extracorporeal therapy
OT  - kidney injury
OT  - unfractionated heparin
EDAT- 2018/02/09 06:00
MHDA- 2018/08/22 06:00
CRDT- 2018/02/09 06:00
PHST- 2015/07/23 00:00 [received]
PHST- 2016/04/14 00:00 [revised]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2018/08/22 06:00 [medline]
PHST- 2018/02/09 06:00 [entrez]
AID - 10.1111/vec.12696 [doi]
PST - ppublish
SO  - J Vet Emerg Crit Care (San Antonio). 2018 Mar;28(2):122-129. doi: 
      10.1111/vec.12696. Epub 2018 Feb 8.